Organogenesis (NASDAQ:ORGO – Get Rating) and Imunon (NASDAQ:IMNN – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends and profitability.
Earnings and Valuation
This table compares Organogenesis and Imunon’s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Organogenesis | $450.89 million | 0.63 | $15.53 million | $0.13 | 16.77 |
| Imunon | $500,000.00 | 20.73 | -$35.90 million | ($5.17) | -0.22 |
Organogenesis has higher revenue and earnings than Imunon. Imunon is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Organogenesis | 3.66% | 9.83% | 5.57% |
| Imunon | -7,179.40% | -68.12% | -47.70% |
Risk and Volatility
Organogenesis has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Imunon has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500.
Insider and Institutional Ownership
47.0% of Organogenesis shares are held by institutional investors. Comparatively, 6.9% of Imunon shares are held by institutional investors. 34.4% of Organogenesis shares are held by company insiders. Comparatively, 4.7% of Imunon shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Organogenesis and Imunon, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Organogenesis | 0 | 2 | 0 | 0 | 2.00 |
| Imunon | 0 | 0 | 2 | 0 | 3.00 |
Organogenesis presently has a consensus target price of $11.00, indicating a potential upside of 404.59%. Given Organogenesis’ higher probable upside, equities analysts plainly believe Organogenesis is more favorable than Imunon.
Summary
Organogenesis beats Imunon on 10 of the 14 factors compared between the two stocks.
About Organogenesis
Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.
About Imunon
Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.
